Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) – Investment analysts at SVB Leerink reduced their Q2 2022 earnings estimates for Calithera Biosciences in a note issued to investors on Tuesday, May 10th. SVB Leerink analyst J. Chang now forecasts that the biotechnology company will post earnings of ($0.13) per share for the quarter, down from their prior forecast of ($0.12). SVB Leerink has a “Outperform” rating and a $2.00 price objective on the stock. SVB Leerink also issued estimates for Calithera Biosciences’ Q4 2022 earnings at ($0.10) EPS.
A number of other research firms also recently commented on CALA. StockNews.com started coverage on shares of Calithera Biosciences in a research report on Thursday. They issued a “hold” rating on the stock. LADENBURG THALM/SH SH reduced their target price on shares of Calithera Biosciences from $3.00 to $1.50 in a research note on Wednesday. Finally, Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Calithera Biosciences has a consensus rating of “Hold” and a consensus target price of $2.00.
Calithera Biosciences (NASDAQ:CALA – Get Rating) last posted its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). During the same quarter in the previous year, the company earned ($0.28) earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in CALA. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Calithera Biosciences during the third quarter worth about $27,000. Bailard Inc. purchased a new stake in shares of Calithera Biosciences during the first quarter worth about $49,000. Tudor Investment Corp Et Al purchased a new stake in shares of Calithera Biosciences during the third quarter worth about $59,000. Truist Financial Corp acquired a new stake in shares of Calithera Biosciences in the first quarter worth approximately $81,000. Finally, Virtu Financial LLC boosted its position in shares of Calithera Biosciences by 1,205.4% in the fourth quarter. Virtu Financial LLC now owns 232,198 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 214,410 shares during the last quarter. Institutional investors and hedge funds own 55.84% of the company’s stock.
Calithera Biosciences Company Profile (Get Rating)
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.